BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Embolism, Atrial Fibrillation and Venous Thrombosis
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT02537405
Bioequivalence Study of Rivaroxaban
Phase 1
Completed
- Conditions
- Embolism, Atrial Fibrillation and Venous Thrombosis
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT02537457
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- Other: Correlation assessment
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT02536534
Atrial Fibrillation Screening With a Smartphone Device and iECG Application
Withdrawn
- Conditions
- Atrial Fibrillation
- Interventions
- Other: AF screening
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Bayer
- Registration Number
- NCT02534532
Proportion of Hysterectomy After Female Sterilization
Completed
- Conditions
- Hysterectomy
- Interventions
- Device: Hysteroscopic device placement including Essure (ESS305, BAY1454032)Procedure: Tubal ligation
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2016-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10578
- Registration Number
- NCT02532361
Retrospective Claims Analysis of Hysterectomy After Sterilization
Completed
- Conditions
- Contraception
- Interventions
- Procedure: Laparoscopic tubal ligationProcedure: Hysteroscopic sterilization
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19317
- Registration Number
- NCT02527278
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1163
- Registration Number
- NCT02518698
Observational Study on Contraception With Essure in France
Completed
- Conditions
- Contraception
- Interventions
- Device: ESS305 (Essure, BAY1454032)
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2644
- Registration Number
- NCT02510443
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Phase 3
Completed
- Conditions
- Peripheral Artery Disease
- Interventions
- Drug: Rivaroxaban-Placebo
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6564
- Registration Number
- NCT02504216
Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 47
- Registration Number
- NCT02497716
- Locations
- πΊπΈ
Children's Hospital Oakland, Oakland, California, United States
πΊπΈRiley Hospital For Children, Indianapolis, Indiana, United States
πΊπΈCarolinas Healthcare System, Charlotte, North Carolina, United States
Β© Copyright 2025. All Rights Reserved by MedPath